Nardil (Phenelzine) Drug Information: Clinical Pharmacology

Pill Identifier Search

May 27, 2012

Nardil

Narcolepsy »

What is narcolepsy?

Narcolepsy is a chronic disease of the central nervous system. Excessive daytime sleepiness (EDS) is the main symptom and is present in 100% of patients with narcolepsy. Other primary symptoms of narcolepsy include:

loss of muscle tone (cataplexy),
distorted perceptions (hypnagogic hallucinations), and
inability to move or talk (sleep paralysis).

Additional symptoms include disturbed nocturnal sleep and automatic behavior (patients carry out certain actions without conscious awareness). All of the symptoms of narcolepsy may be present in various combinations and degrees of severity.

Narcolepsy usually begins in teenagers or young adults and affects both sexes equally. The first symptom to appear is excessive daytime sleepiness, which may remain unrecognized for a long time in that it develops gradually over time. The other symptoms can follow excessive daytime sleepiness by months...

Read the Narcolepsy article »

« Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
Next »

Nardil User Reviews >>

Nardil

Understanding Depression Slideshow

Take the Depression Quiz

Benefits of Treating Depression

font size

CLINICAL PHARMACOLOGY

Monoamine oxidase is a complex enzyme system, widely distributed throughout the body. Drugs that inhibit monoamine oxidase in the laboratory are associated with a number of clinical effects. Thus, it is unknown whether MAO inhibition per se, other pharmacologic actions, or an interaction of both is responsible for the clinical effects observed. Therefore, the physician should become familiar with all the effects produced by drugs of this class.

Pharmacokinetics

Absorption — Following a single 30 mg dose of NARDIL® (phenelzine) (2 X 15 mg tablets), a mean peak plasma concentration (Cmax) of 19.8 ng/mL occurred at a time (Tmax) of 43 minutes postdose.

Metabolism — NARDIL® (phenelzine) is extensively metabolized, primarily by oxidation via monoamine oxidase. After oral administration of ¹³C₆-phenelzine, 73% of the administered dose was recovered in urine as phenylacetic acid and parahydroxyphenylacetic acid within 96 hours. Acetylation to N²-acetylphenelzine is a minor pathway.

Elimination — The mean elimination half-life after a single 30 mg dose is 11.6 hours. Multiple dose pharmacokinetics have not been studied in man.

Last reviewed on RxList: 8/29/2007
This monograph has been modified to include the generic and brand name in many instances.